NASDAQ:VERA

Vera Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VERA

*Your capital is at risk

$31.58

-1.31 (-3.98%)

At Close: Aug 10, 2026

Vera Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 3.21. In total, the insiders bought 1.9M and sold 227.93K VERA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	3.21
● Buy	1.9M shares
● Sell	227.93K shares
71% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Jul 07, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 20, 2026 Buy	Class A Common Stock	Skelton Laurence Matthew Chief Commercial Officer	Officer	0 Value: $0
Jan 20, 2026 Buy	Class A Common Stock	Skelton Laurence Matthew Chief Commercial Officer	Officer	0 Value: $0
Jan 20, 2026 Buy	Stock Option (right to buy)	Skelton Laurence Matthew Chief Commercial Officer	Officer	60 000 Value: $2.51M
Jan 20, 2026 Buy	Stock Option (right to buy)	Skelton Laurence Matthew Chief Commercial Officer	Officer	31 500 Value: $919.2K
Dec 15, 2025 Sell	Class A Common Stock S-Sale	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $500.8K
Dec 15, 2025 Buy	Class A Common Stock M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 15, 2025 Buy	Stock Option (right to buy) M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 11, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	5 882 Value: $250.0K
Dec 08, 2025 Sell	Class A Common Stock S-Sale	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $453.1K
Dec 08, 2025 Buy	Class A Common Stock M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 08, 2025 Buy	Stock Option (right to buy) M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 03, 2025 Sell	Class A Common Stock S-Sale	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $400.0K
Dec 03, 2025 Buy	Class A Common Stock M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Dec 03, 2025 Buy	Stock Option (right to buy) M-Exempt	Turner William D. Chief Regulatory Officer	Officer	10 000 Value: $155.3K
Nov 25, 2025 Buy	Common Stock J-Other	Meyers James R Insider	Other	0 Value: $0
Nov 25, 2025 Buy	Stock Option (right to buy) A-Award	Meyers James R Director	Director	25 000 Value: $735.8K
Nov 21, 2025 Sell	Class A Common Stock S-Sale	Carter Jason S Chief Legal Officer	Officer	3 864 Value: $107.5K
Nov 13, 2025 Buy	Class A Common Stock M-Exempt	Young Joseph R SVP, Finance, Chief Acct Offcr	Officer	10 000 Value: $39.4K
Nov 13, 2025 Buy	Stock Option (right to buy) M-Exempt	Young Joseph R SVP, Finance, Chief Acct Offcr	Officer	10 000 Value: $39.4K
Nov 11, 2025 Sell	Class A Common Stock S-Sale	Young Joseph R SVP, Finance, Chief Acct Offcr	Officer	15 000 Value: $435.9K
Jun 24, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	27 071 Value: $605.1K
Jun 24, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	13 536 Value: $302.6K
Jun 24, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	13 536 Value: $302.6K
Jun 24, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	27 071 Value: $605.1K
Jun 23, 2025 Buy	Class A Common Stock P-Purchase	Enright Patrick G Director	Director	139 595 Value: $2.91M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VERA THERAPEUTICS, INC.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...

Read Full Profile Here